3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
31
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Endometrial Neoplasms
11
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
4
Vulvar Neoplasms
3
Peritoneal Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cervical Cancer Stage IB1
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Anus Neoplasms
1
Anastomotic Leak
1
Interventions
pembrolizumab
33
Paclitaxel
27
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Fulvestrant
15
fludarabine
14
Trastuzumab
14
aldesleukin
13
Docetaxel
13
Early Intervention, Educational
12
Surveys and Questionnaires
11
veliparib
10
palbociclib
10
Methods
10
Gemcitabine
10
Blood Specimen Collection
10
Nivolumab
9
Flow Cytometry
9
Biopsy
9
Bevacizumab
9
sargramostim
8
niraparib
7
liposomal doxorubicin
7
Therapeutics
7
Taxes
7
Standard of Care
7
Psychiatric Rehabilitation
7
Magnetic Resonance Spectroscopy
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Indocyanine Green
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled